Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(13):961; doi:10.1093/jnci/93.13.961-a
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Arnold, K.
Right arrow Articles by Eckstein, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Arnold, K.
Right arrow Articles by Eckstein, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 13, 961, July 4, 2001
© 2001 Oxford University Press

MEMORANDUM FOR: Science Writers and Editors on the Journal Press List

Tamoxifen Therapy for Breast Cancer Reported to Increase Risk of Estrogen Receptor-Negative Tumors in the Contralateral Breast

June 28, 2001 (EMBARGOED FOR RELEASE 4 P.M. EDT July 3)

Katherine Arnold, Deputy News Editor, Dan Eckstein, (301) 986-1891, ext. 112

A new study shows that giving tamoxifen to women with breast cancer decreases their risk of developing cancer in the contralateral (opposite) breast that is estrogen receptor (ER) positive, but it possibly increases their risk of developing an ER-negative tumor. Nevertheless, an accompanying editorial questions the conclusions and raises the question of whether these findings can be translated into clinical practice.

The findings are presented by Christopher Li, M.D., M.P.H., and colleagues at the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?